NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Atrium Therapeutics, Inc. (RNA) Stock Analysis

Atrium Therapeutics, Inc. (RNA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

RNA

$8.00

+$0.02 (+0.25%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RNA with… →

RNA Key Statistics

As of Oct 21, 2026
Trading
Open
$7.97
Previous Close
$7.98
Day's Range
7.96–8.32
52-Week Range
7.49–16.77
Volume
193.21K
Valuation
Market Cap
$136.85M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.82
EPS (ttm)Profit attributable to each share over the last twelve months.
−5.44
Financials (FY)
Revenue (FY)
$18.62M+70.85%
Net Income (FY)
−$76.68M
Profit marginThe share of revenue left as profit after all costs and taxes.
−184.15%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
17.11M
1-Year Return
−83.69%
Dividend and dates
Earnings Date
November 9, 2026estimated
Avg Volume
262.31K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, RNA closed at $8.00, −83.69% over 1 year.

Atrium Therapeutics, Inc. (RNA) has a market capitalization of $136.85M.

In fiscal 2025, RNA reported revenue of $18.62M.

RNA Stock Return by Calendar Year

Atrium Therapeutics, Inc. (RNA) return since Dec 2024: what $10,000 became

1 year
$10,000 $1,631
−83.69%
Since Dec 2024
$10,000 $2,576
−74.24%

If you had invested $10,000 in Atrium Therapeutics, Inc. (RNA) at the close on December 19, 2024, the earliest close on record here, it would have been worth $2,576 at the close on October 21, 2026: −74.24% in total, −52.20% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−88.91%
2025+148.04%
2024 (partial year)−6.34%

As of October 21, 2026.

RNA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$18.62M−$76.68M−411.9%
2024$10.90M−$25.12M−230.5%
2023$9.76M−$6.39M−65.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$18.62M—−$76.81M−$76.68M−411.9%
2024$10.90M—−$13.22M−$25.12M−230.5%
2023$9.76M—−$6.39M−$6.39M−65.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

RNA Valuation vs Biotechnology Median

Median of 608 stocks
MetricRNABiotechnology medianvs median
P/S ratio3.8213.300.3x the median
Profit margin−184.15%−38.31%145.8 pts below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 10 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Atrium Therapeutics, Inc. (RNA) carries a market capitalisation of $136.85M. It is classified in the Biotechnology industry, within the Healthcare sector.

The most recent close on file for RNA is $8.00, dated October 21, 2026. That is +$0.02 (+0.25%) against the previous close. The 52-week range on file runs from $7.49 to $16.77. The latest close sits 6.81% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $18.62M. Against the prior fiscal year total of $10.90M, that is a change of +70.85%. The same year closed with a net loss of $76.68M. The reported profit margin is −184.15%. That is 145.8 percentage points below the Biotechnology median of −38.31%. Earnings per share on a trailing basis come to −5.44.

Across the 3 fiscal years on file, revenue moves from $9.76M in 2023 to $18.62M in 2025. Of those 3 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 3.82 times revenue. On price-to-sales that is 0.3 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Over the trailing twelve months the total return is −83.69%. The stored price history starts on December 19, 2024, and the total return since then is −74.24%. Daily returns over the trailing 1 year annualize to a volatility of 100.99%.

Growth & Income

The record shows no dividend for RNA.

The record holds one complete calendar year, 2025, which returned +148.04%. 2026 is still running; the total return is −88.91% year to date.

Peer Comparison

Atrium Therapeutics, Inc. (RNA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Atrium Therapeutics, Inc. RNA $136.85M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Atrium Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Atrium Therapeutics, Inc.

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.

Visit website →